There has been a great deal of public concern regarding the possibility that the use of mobile phone-related technologies might result in adverse health effects. Corresponding to this, there has been substantial epidemiological research designed to determine whether the use of mobile phones (MP) has any effect on health, and in particular whether it increases the risk of developing head and neck tumours. Such literature is particularly heterogeneous, which makes it difficult to pool in a meta-analysis. This paper thus reviews the epidemiological literature pertaining to the use of mobile phones and mobile phone-related technologies, and head and neck tumours, in an attempt to consolidate the various reports. Although there have been individual reports of associations between MP-use and tumours, this research is not consistent and on balance does not provide evidence of an association. There are reports of small associations between MP-use ipsilateral to the tumour for greater than 10 years, for both acoustic neuroma and glioma, but the present paper argues that these are especially prone to confounding by recall bias. The reported associations are in need of replication with methods designed to minimise such bias before they can be treated as more than suggestive.
Introduction
The use of mobile (cellular) phones (MPs) has gone from a rare novelty in the mid 1980s to almost ubiquitous use today, with over two billion phones currently in operation internationally and demand expected to further rise as more owners acquire two or more MP accounts 1 . MPs send and receive voice and packet data via the transmission of radiofrequency (RF) electromagnetic field (EMF) signals, using a variety of digital transmission protocols. When held against the ear, some of the transmitted RF EMF from the MP, up to ~50% depending on the model, is absorbed in the head and hand, prompting fears about possible adverse effects from this exposure. To address this concern, a number of organizations have invested in epidemiological research to look for relations between MP-use and adverse health consequences, particularly the induction and/or promotion of tumours. To date, this epidemiology research has only led to further debate, with different results from different research groups. One of the largest epidemiology studies to date focusing on MPs and cancer outcomes (Interphone 2 ) is shortly expected to produce more reliable results than has been possible in the past. As such, it is an opportune time to take stock of the MP epidemiology literature to date. The present paper thus provides a review of this literature, assessing the consistency of patterns across studies, and discussing important methodological issues.
There have been numerous bodies formed to help guide research in determining whether there are adverse consequences of mobile phone use. It is noteworthy that the vast majority of these have recommended epidemiology as an important part of the research solution [3] [4] [5] . Epidemiology is typically referred to as the study of disease patterns in human populations, with the principal goal the identification of causes and determinants of disease. Thus the question that research-guiding bodies have asked is whether by studying relationships between MP-usage patterns and disease outcomes in human populations, we can determine if MPs have been causing adverse health consequences. During conventional hand held use, the majority of MP exposure is typically absorbed by the brain and meningeal tissues closest to the surface of the head, the parotid gland and the vestibular portion of the eighth cranial nerve [6] [7] . The MP-epidemiology effort has accordingly focused primarily on tumours of the head and neck region.
This MP-tumour epidemiology research has varied greatly in study design. For example, some studies have simply described cancer incidence and MP use in the population at large (ecological studies), whereas others have employed analytical case-control designs. Further, some of the case-control studies have employed hospital patients as controls, whereas others have recruited population-based controls. Some have reported on relationships between reported MP use and specific tumour types (such as acoustic neuroma or meningioma), while others have treated all intracranial tumours as being similar, and reported on relationships between MP use and cancer more generally. This heterogeneity in study design makes it more difficult to draw conclusions from the literature as a whole, and is particularly problematic for meta-analyses. In order to reduce the potentially obscuring nature of this heterogeneity, this paper will thus discuss individual studies with only a brief discussion of meta-analyses and their limitations in this field.
Materials and methods

Literature search strategy
We conducted a Medline search from January 1966-October 2007 (inclusive) using the key words: cellular (tele)phone or mobile (tele)phones; case-control studies or cohort studies; brain tumours; acoustic neuroma; vestibular schwannomas; glioma; glial cell tumours; meningioma; brain neoplasms; electromagnetic fields; radiofrequency energy or radiation exposure and bio-effects of non-ionising radiation. Only studies published in English were included. Additional articles known to the authors within the search period were included.
Meta-analyses and the MP-tumour literature
Three meta-analyses have been conducted. Lahkola et al (2006) 8 combined results from 11 case-control and 1 cohort study (9 population-and 3 hospital-based) to assess possible relations between intracranial tumours and MP use up to 5 years. No overall association was found (OR=0.98 [95%CI 0.83-1.16] * ) and this was unrelated to study base or tumour type. The review did not provide ORs for pooled analyses by latency, but noted little evidence for increasing risk with duration of use. Hardell et al (2007) 9 combined results from case-control studies reporting cases with > 10 years exposure to MPs (for acoustic neuroma, meningioma and glioma separately). The studies included in the analyses were selected according to the authors' classification of the study's methodological rigor, and included 2 to 6 studies for different analyses. No association was reported overall for any tumour type (acoustic neuroma 1. Thus there is considerable variability in terms of analyses conducted and results reported, with the only consistent finding being that all reported no overall association with increased risk. However meta-analysis of observational epidemiological studies is always fraught, and it is difficult to know how useful are these pooled results. Perhaps the main issue here is that heterogeneity in this research domain is substantial, and this needs to be accounted for in any meta-analysis. Unfortunately the methods used to detect and account for such heterogeneity require larger numbers of studies than are available, and so unless we can be confident that studies have been conducted in a similar manner, it is difficult to draw conclusions from the pooled results.
As an example, Lakhola et al 8 combined glioma, meningioma and acoustic neuroma cases, which are very different tumours (see below) with different aetiologies, biological behaviour and prognosis. They also combined studies whose quality of exposure assessment was highly variable without weighting for potential exposure misclassification or other biases or confounders. All of these factors introduce clinical heterogeneity, which makes the results difficult to interpret, and as the number of studies in these meta-analyses is limited, it is difficult to measure or account for such heterogeneity statistically. Similarly, there are some methodological aspects in Hardell et al 9 and Kan et al 10 which may be questionable, with no strong reason given for excluding the Danish cohort study 18 , and the choice of risk estimates for pooling in Hardell et al 9 lacking objective justification.
Statistics and patterning of results
Many view the major aim of epidemiological investigation as the estimation of effect size 11 , whereas others are keen to establish whether such estimates are unlikely to have arisen by chance (e.g. insisting that they are associated with probabilities < 0.05). While each approach has strengths and weaknesses, this review focuses on statistical significance and confidence intervals. An important limitation with this approach is that we cannot look at each comparison in isolation, but must consider all comparisons in order to interpret the individual comparison. For example, it would be expected that at least 1 comparison was significant at the p=0.05 level from a group of 20 independent comparisons, and so knowledge of all other comparisons (both published and unpublished) and their degree of independence is needed in order to interpret each comparison. However this is not possible. It is with this in mind that the review below treats the patterning of results, both within and between studies, as particularly important in evaluating the literature as a whole.
Grouping of studies of epidemiology of tumours and MPs
Research separately, while Hardell et al 13 conducted analyses for each of a number of different types of glioma separately (e.g. high-and low-grade astrocytoma), and also provided a grouped analysis of malignant tumours such that it included medulloblastoma and 'other' non-gliomas. Thus it is not possible to directly compare the results of the two studies.
However, consolidation of data is required in the evaluation of the MP-tumour literature as there are not enough data available on each of the different combinations of study designs to provide useful information pertaining to each combination separately. Thus, this review will discuss the literature in terms of: 1/ analyses performed separately on the benign tumour acoustic neuroma, neurinoma or Schwannoma (Acoustic Neuroma, ICD-O 9560), 2/ analyses performed separately on the usually benign tumour meningioma (Meningioma, ICD-O 9530-9539), 3/ analyses performed on the grouped subtypes of the usually malignant tumour glioma (Glioma, ICD10 C71, ICD-O 9380-9480), and 4/ analyses where tumour types have been treated as homogeneous (Combined Tumours). Different research designs will also be grouped where appropriate.
It should also be noted that studies have looked for relations between MP-use and specific tumours other than those described above. There is not enough consistency to enable comparison and so these will only be considered in so far as they contribute to the Combined Tumours.
Results
For each study, analyses are reported (where data is available) in terms of: 1/ overall results (i.e. analyses of grouped data, including by tumour type where applicable, not divided by such factors as latency); 2/ laterality results; 3/ latency results; 4/ magnitude of exposure (duration and frequency of use); and 5/ combinations of these factors. Results are for analogue/digital MPs, either combined or separately, and do not include cordless phones except where specified.
Incidence and mortality trends
Cook et al 14 analysed the incidence of malignant tumours of the brain, head and neck in New Zealand during a period of substantial MP-technology uptake (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) . No increase in incidence rate was found over this period for either males or females. Hardell et al 15 analysed incidence trends of intracerebral tumours in Sweden (1960-1998). Acoustic neuroma incidence increased over 1980-1998 but not 1960-1979, and malignant tumour incidence was unchanged over this period. As the acoustic neuroma trend was mostly driven by those who used phones less (the older age groups), this trend is unlikely to be related to MP use. Lönn et al 16 analysed incidence trends of intracerebral tumours in four Nordic countries (Denmark, Finland, Norway, Sweden; 1969-1998). Incidence rates increased during the period corresponding to improved diagnostic methods (late 1970s to early 1980s), and was unchanged over the period of increasing MP use (after 1983). The pattern was similar specifically for glioma. Roosli et al 17 analysed brain tumour mortality rates in Switzerland . Mortality rates increased during the period before MPs were introduced (before 1987), but not post 1987 (when MP use increased exponentially). Thus the ecological studies, which are often considered relatively weak designs, do not provide evidence of increased brain tumour incidence/mortality related to MP use.
Retrospective cohort design
Johansen et al 18 conducted a retrospective cohort study, comparing incidence of a variety of cancers (including acoustic neuroma, meningioma and glioma) in 420,095 MP subscribers (Denmark; 1982 -1985 ]) or combined 'brain and nervous tumours' (0.97, CI not specified). The combined 'brain and nervous tumours' results were independent of latency, but a latency breakdown was not provided for individual tumour types. Although these studies have good statistical power owing to the large cohort size, and provide a lengthy follow-up period, SchĦz et al acknowledge limitations in their design, in particular that the protocol is not able to identify the user of the mobile phone, but rather the name in which the mobile phone subscription is held. This may lead to exposure misclassification, which in any case is crude as it takes no account of the duration or frequency of use, but merely years of subscription. The authors also note that a large number of potential subjects were excluded from the cohort as the subscriptions related to corporate accounts, for which the identity of the actual user was even less certain. This group may have represented particularly high usage and introduced a bias into the analysis.
Hospital-based case-control design
Muscat et al 20 ; 1995-2000) . No association between MP use and acoustic neuroma was identified (1.0[0.4-2.2]), and associations with laterality or latency were not tested.
Thus 3 hospital-based case-control studies have not identified an association between MP use and acoustic neuroma, meningioma, glioma or combined tumours. However it should be noted that the use of hospital controls may overmatch for exposure, and may be unrepresentative of the general population in other ways that makes it difficult to identify a relationship.
Population-based case-control designs
Hardell et al 24 , as a function of laterality, latency or duration of MP use, for tumours in different lobes separately, or for laterality at different lobes separately. An association between MP-use and ipsilateral tumours was reported, but this was not statistically significant. Some of these results have been reported elsewhere by Hardell et al 25, 26 , and so the latter should not be read as replications of the original study 24 , or as additional support for the claimed associations.
Auvinen et al 27 ]), but it was similar for analogue phones. The risks for analogue and cordless MPs decreased with latency from 1-5, 5-10, and to >10 years, and the digital ORs were largest for 5-10, then 1-5, then >10 years (although it was reported that when only the >15 year latency was considered, the small sample showed much larger ORs). Risks were also increased for the higher cumulative exposure to analogue (13 [38] [39] [40] [41] , and so should not be viewed as independent of but rather as superseding those studies. The earlier acoustic neuroma and glioma studies will not be discussed separately. No association between MP use and acoustic neuroma was found, overall (OR=0.9[0.7-1.1]) or for digital and analogue MPs separately, nor was there an association of diagnosis with laterality, latency or cumulative exposure, whereas marginally decreased risks were associated with ipsilateral use for latencies up to 4 years (82 cases, OR=0.7 [0.5-0.9]) and for lifetime years of use up to 4 years (111 cases, OR=0.8[0.6-1.0]). A marginally raised risk of acoustic neuroma was also found on the same side of the head on which the phone was reported to be used, among those who had used a phone for > 10 years (23 cases; OR=1.8[1.1-3.1]). A statistically significant overall association between MP use and decreased risk of glioma was found (OR=0.78[0.68-0.91]), but there was no association of diagnosis with laterality, latency or cumulative exposure. However, as for acoustic neuroma, they did report a marginally raised risk of glioma on the same side of the head on which the phone was reported to be used, among those who had used a phone for > 10 years (77 cases; OR=1. 39 
Discussion
In evaluating the above results, it is important to consider a few issues that will aid in interpretation. These issues are first discussed, followed by an evaluation of the literature separately for analyses of different tumour types. Note that the discussion follows the same structure as the results section in terms of analysis types. A brief consideration of how these results relate to the upcoming Interphone pooled analysis is then given.
Methodological issues
Grouping of different tumour types
Reporting analyses that group tumour types together increases the number of cases and hence the statistical power for any given analysis. This can provide an opportunity to address other issues, such as relations between MP-use and tumour location that may not otherwise be possible due to small case numbers. However there are limitations with this approach, in that different tumour types generally have different causes and courses, which makes meaningful interpretation of grouped results difficult. For example, should a relationship between MP use and tumours with different aetiologies be found, it would be difficult to explain how one type of exposure could have caused all the tumours. While this situation does occur for ionising radiation, the mechanisms important for ionising interactions, which produce gross molecular damage in tissues independent of their type, are not available for the non-ionising emissions produced by MPs. The review of 'grouped' analyses needs to be read with this limitation in mind.
Small groupings -While it is possible that particular combinations of exposure characteristics (e.g. ipsilateral with >10 years latency) may be required to detect an increase in tumour incidence with typical epidemiological methods, such combinations can also be difficult to evaluate as they may be based on small numbers of cases, which can result in less reliable risk estimates than large numbers and can increase the chance of spurious results. Corresponding to this it is important to distinguish between the total number of cases in a study (which can be large), and that of the particular analysis (which can be small).
Recall and other biases -Case control studies are notoriously prone to bias. To minimise selection bias, the cases recruited need to be representative of the target condition. With the development of population based cancer registries, in Australia and many other Western countries, this has usually been achieved for glioma. However in many countries, for non-malignant conditions such as acoustic neuroma and meningioma, case ascertainment requires notification by neurosurgeons, radiologists, pathologists or other medical specialists and is inevitably incomplete. Probably even more critical to the validity of the findings is that the controls need to be representative of the population from which the cases arose. This is why population-based case control studies are generally preferred to hospital-based studies. Even Interphone 2 , which is arguably the best available study to address the present issue, has an overall participation rate of potential controls of 53% (range 35-74%). In other words, in many centres over half the eligible controls refused or were unable to participate, which raises the possibility of substantial selection bias.
Furthermore exposure to RF from mobile phones is typically assessed by questionnaire (see Inyang et al 45 for a critique of limitations of this approach), and an important consideration in assessing the studies of brain tumours is the likelihood of substantial recall bias that this introduces. Cases typically ruminate over their condition and may be much more likely to recall the details of their mobile phone use than are controls who are typically normal healthy members of the community. Conversely, glioma and its treatment can impair memory and result in less accurate recall of exposure by cases. In both situations there is differential misclassification of exposure which can bias ORs 13 . For example Hepworth et al 41 argued that their British interphone results were due to recall bias, as it was found that ORs were significantly higher/lower for MP-use ipsilateral/contralateral to glioma tumours. Some research groups have made substantial progress in estimating the effects of exposure misclassification, notably so with the Interphone protocol where support for under-reporting of number of calls and over-reporting of duration of calls was found (e.g. Vrijheid et al 46 ). Such quantification will improve interpretability of results, providing an estimate of the error associated with certain biases, which in turn provide an indication of whether biases are large enough to account for the results. Dose -Many researchers have used 'dose' as a means of exploring whether particular associations are real or merely chance findings, where 'dose' may refer to a number of metrics, such as years of exposure or cumulative call time or number of calls 13, 34 . There is disagreement as to the best metric to use, with some arguing that cumulative call time is superior 39 , some advocating number of calls per day 47 , and others arguing for the importance of both metrics 35 . However, should the hypothesis that 'RF energy causes tumours' be correct, then it would be expected that each of these metrics would be related to tumour outcomes.
Laterality -Related to this is 'laterality'. It is generally thought that laterality may be important when considering the patterning of results, as the vast majority of energy is absorbed ipsilateral to the ear of use, whereas there is virtually no energy absorbed on the contralateral side 6, 7 . Thus it would be expected that if the RF energy was causing tumours, that the tumour would be more likely to occur ipsilateral to the side of use, and that if only a contralateral OR increase was found, it would likely be due to chance (or a form of systematic error). Thus support for an effect is generally assumed to result from significant increases in ipsilateral but not contralateral ORs.
However it is important to note that interpretation of differences between ipsilateral and contralateral risk is complicated by a number of factors, such as the recall biases discussed above. For example, while a finding of increased ipsilateral and decreased contralateral ORs is generally interpreted as recall bias (Hepworth et al 41 ) , this is also consistent with an even larger increase for ipsilateral exposure (and a contralateral OR close to unity), with both being reduced due to the reported bias towards reduced ORs overall 46 . The corollary of this is that without stronger dosimetry (for example the use of hardware modified phones with tilt sensors), there will always be uncertainty regarding whether larger ORs for reported ipsilateral than contralateral exposures are the result of reporting bias or real effect. As it is not feasible at present to widely employ such strong dosimetry, unless the comparison between ipsilateral and contralateral ORs is so stark as to exceed potential bias (and this does not appear to be the case), then reports of laterality associations arising in the MP health effects literature are of limited utility and should be regarded with caution.
Latency -Latency should be distinguished from dose, as it does not refer to how long someone has used a MP for, but rather how long since they started using a MP. Thus a person may have used a MP only rarely (low dose), but the first use may have been a long time ago (long latency). Corresponding to this, latency is important not as a measure of how much exposure some have had, but rather in terms of the time that they've had for any changes to sub-cellular processes to occur, which is important as many cancers have a latency period of > 10 years.
Causation -Epidemiology alone cannot determine whether any disease is caused by a given environmental exposure. Certain considerations aid in determining whether an association is likely to be causal (e.g. the Bradford Hill criteria 48 ), but in general it is very difficult to conclude that such an association is causal.
Incidence and mortality data
As can be seen from the above incidence and mortality data, it is clear that there is no evidence of large increases in intracerebral tumours over time that corresponds to the substantial uptake of MP technologies. The only suggestion of such a change was an increase in acoustic neuroma incidence from 1980-1998 reported by Hardell et al 15 , but as this was related to those who used MPs less during that period (older cases), the authors concluded that this was not likely related to MP use. Further to the possibility of no association, this leaves open two other possibilities. First is that there may not have been enough time to detect an effect of MPs. This is feasible in that these studies only looked at incidence/mortality until 1998, and as tumours may take over 10 years to develop and as the majority of MP uptake was from the 1990s, they may not have been ideally positioned to assess this issue. Second is that these ecological analyses were not sensitive enough to detect very small effects, and so it may be that MPs have a very small effect on tumours that were too small to be detected by these studies.
Case-control and cohort studies with individual patient data offer more sensitive and valid means of assessing possible effects of MPs on tumours. These will be discussed separately for each tumour type (acoustic neuroma, meningioma, glioma, combined).
Acoustic neuroma
Acoustic neuroma is a benign intracranial primary tumour of myelin forming cells of the vestibulocochlear (eighth cranial) nerve. It is sometimes but rarely associated with neurofibromatosis. To date, 10 independent publications have reported on possible relationships between acoustic neuroma and MP use (Table 1) , and although there have been a number of interesting findings, there has been no overall consensus on the issue.
In terms of overall increases in risk (i.e. ORs with no separation based on such factors as laterality and exposure duration), only the Hardell group have reported associations with MP use, and these have not been consistent with one another (analogue but not digital 13 ; analogue and digital 34 ), with the stronger findings from the study with a substantially smaller sample (84 cases 34 ). These reports contrast sharply with the remaining studies where no relationships were reported 19, [21] [22] [23] [24] 35, 42, 44 . Although some [21] [22] [23] used hospital-controls which may reduce the validity of the study, the consistency of these hospital-based case-control results with those from the Interphone studies 35, 42, 44 (which contained over three times the number of cases as the Hardell studies combined), provides a strong indication that there is no overall effect. Further arguing for the lack of association is that these Interphone results come from 8 independent research groups, which followed a common and strong protocol. The Interphone pooled analysis will be important to clarify this issue, but at present the literature as a whole does not demonstrate a relation between overall MP use and acoustic neuroma, and we must look to more detailed patterns of results to determine whether there are any such relationships.
In terms of overall laterality (i.e. not looking at laterality for particular doses or latencies), there has only been one report of this 34 , which was for both digital and cordless but not analogue MPs, one report of reduced contralateral risk 21 , and three null reports 22, 35, 42 . Contrary to the significant overall risk for analogue and digital MPs (described above), this laterality result was for digital and cordless only, and laterality was not reported by Hardell et al 13 . Thus when we consider the number of comparisons made across these studies, that the positive finding was only for the phone types with the lower time averaged maximum transmitter power (digital and cordless but not analogue), and the strength and number of cases in the Interphone studies contributing to the null results, this lack of replication across studies argues strongly against there being an overall laterality effect.
In terms of the latency since first use, increased risk for > 5 years but not > 10 years (for analogue phones only) was reported 13 , which would not be expected if long latencies were required for tumour development. Furthermore, Hardell et al 34 reported a relation between latency and OR for both analogue and digital MPs, but it was in the opposite direction to what would be expected if MPs were associated with tumour promotion in that ORs were larger for shorter latencies ('1-5 year' > '5-10 year' > '10 year' latency). It was suggested in Hardell et al 34 that this trend was not important given that the >15 years latency OR was large, but as this was based on only 4 cases it is not clear that this evidence is strong enough to rebut the decreasing trend. Furthermore, the other studies failed to identify a latency effect 13, 22, 35, 42 (which includes the strengths described above of Interphone 35 ). For dose, only one study has reported increased risk as a function of cumulative call time 34 , with three null results 22, 35, 42 and one study reporting reduced risk as a function of number of calls 44 . Overall, the only relationships reported are therefore not strong enough to support the thesis that greater cumulative dose or exposure latency is associated with acoustic neuroma.
There have not been any reports of increased risks for ipsilateral high cumulative doses, and there has been one report of increased 35 and one of no change 42 to ORs for >10 years of use ipsilateral to the tumour, with this result relating to the combination of both analogue and digital MPs. Although the positive result comes from the Interphone group, and is therefore a strong design, it contrasts with the only other study reporting this (also from Interphone albeit from a much smaller sample), and as the finding was based on only 23 cases, and as cumulative exposure was not related to ipsilateral acoustic neuromas, we must await replication and the final pooled Interphone results before we can be confident with this result. Further, as this result is very small and includes the difficulties described above with interpreting laterality results, we do not believe that this represents a strong finding.
Thus in conclusion, while there is no strong evidence Hardell ( for an association between acoustic neuroma and MP use, the literature suggests the possibility of a relation between ipsilateral MP use for >10 years and acoustic neuroma that is difficult to interpret, and needs verification.
Meningioma
Meningioma is the most common benign tumour of the brain and arises from the arachnoidal cap cells of the meninges. Meningioma represents about 15% of primary brain tumours. The tumour is usually dome shaped, well circumscribed and can thus often be surgically resected. The risk of meningioma appears to increase in patients who have received scalp irradiation. To date, 10 independent publications have reported on relations between meningioma and MP use ( Table 1 ). The only report of an overall association has been of reduced risk of meningioma with MP use 40 , with this overall reduction primarily driven by digital as opposed to analogue MP use. As this contrasts with the null results of the other nine studies 12, 13, 19, 22, 24, 27, 34, 38, 43 , this one positive finding does not provide support for an overall relation between MP-use and meningioma.
Similarly, information on laterality of tumour does not provide evidence of increased risk, with the only positive reports being of reduced risk contralateral to MP use 34, 40 (as well as numerous null results 12, 22, 24, 34, 38, 43 ). In terms of latency of use and cumulative exposure, there have been some reports of relations with meningioma in addition to six studies that failed to report such a relation 12, 13, 22, 27, 38, 43 . Hardell et al 34 was the only study to report increased risk with latency (analogue but not digital or cordless) and cumulative dose (analogue, digital and cordless). The findings of Hardell et al 34 thus contrast strongly with the other research, and their interpretation is problematic due to the association also being there for cordless MPs, which, in Sweden during that period, emitted very little energy. Thus the evidence to date does not form any meaningful pattern and suggests that there is no indication of increased risk of meningioma with MP use.
Glioma
Glioma is the most common primary malignant tumour of the central nervous system, which arises from the glial cells. Subtypes of glioma include astrocytoma, ependymoma, oligodendroglioma and mixed cell gliomas depending on the cell of origin. They are usually classified by histological grade, with the most anaplastic tumour known as glioblastoma multiforme. This infiltrates surrounding brain tissue and cannot be completely surgically resected. Although the WHO recognises 4 grades of astrocytoma, most studies in this area have only subclassified gliomas as high or low grade. There are approximately 1,336 new cases of malignant brain tumours in Australia each year, corresponding to an incidence rate of 6.9 cases / 100,000 / year 49 . To date, 7 independent publications have reported on relations between glioma and MP use (Table 2) .
Again, there is little consistency in results when we consider the literature as a whole. In terms of overall associations (not subdivided), there have been four null results 19, 20, 22, 24 , one report of reduced risk for digital 36 , one of increased risk for analogue but not digital 27 and one of increased risk for analogue, digital and cordless MP use 28 . There is thus no substantial increase overall as effects were not detected by a number of studies, including the one with strongest methodology and largest number of cases 36 . However given that there have been two reports of increased risk, one with a large number of cases, it will be important to await the final Interphone pooled analysis before we can confidently conclude that there is no overall association.
When we consider the pattern of results, this does not provide support for an association. In terms of laterality, only Hardell et al 28 reported larger risks ipsilaterally, whereas Lakhola et al 36 reported reduced risks contralaterally and others no association 22, 24 . If anything, this emphasises the difficulty of interpreting laterality (discussed above). There are also no consistent patterns in terms of latency of use or cumulative exposure. Hardell et al 28 reported increased risks with cumulative exposure for each of analogue, digital and cordless phones separately 28 , whereas others did not find a cumulative dose relationship at all 20, 22, 27, 36 . Latency effects were reported for analogue but not digital for one 27 , analogue, digital and cordless for another 28 , and no effects by others 20, 22, 36 . Hardell et al 28 provide the strongest evidence of an overall latency effect (Auvinen et al 27 had a limited latency range), but even this effect is small, with ORs increasing from the '>1-5 year latency' to '>10 year latency', for analogue, digital and cordless MPs. This contrasts with Lahkola et al 36 , and suggests that either there is no effect or there is an effect that is so small that it is barely detectable using current epidemiological techniques.
One finding that is consistent with this last possibility is that Lahkola et al reported increased risk for ipsilateral exposure of >10 years 36 . That is, as this is the combination that would be expected to produce the highest number of cases if there was an underlying association with exposure to MPs, and as the ORs were only small and marginally significant (77 cases; OR=1.39[1.01-1.92), it is possible that this represents a real effect that is too small to be detected in the less sensitive analyses (overall, laterality, latency). However as no other study has reported on this combination (eg. Auvinen et al 27 , Hardell et al 28 ) it is also possible that this is due to chance, and so as with acoustic neuroma it will be important to await the final Interphone pooled analysis to determine whether this is more than a chance finding. It should further be noted that this result is affected by the difficulties described above for laterality findings in general, and at present we must conclude that the literature does not provide evidence of an association between MP use and glioma.
Combined tumour analyses
There have been 6 independent publications testing for associations between MP use and combined tumours (Table 2) . Again, there is little consistency when we consider the literature as a whole. In terms of overall associations (not divided by laterality, level of exposure etc), there have been two reports of increased ORs (analogue 13, 27 ) versus five null reports (analogue 19, 20, 22, 24 , digital 19, 20, 22, 24, 27 ). Thus there would appear to be the possibility of consistency in terms of analogue but not digital MPs, but with the results far from conclusive.
However, two of these publications reported similar risks for analogue, digital and cordless MPs, which suggests that the increased ORs may not be related to the EMF exposure, as these phones result in substantially different patterns of energy absorption in the head, with cordless exposures much lower than the others. It follows that if exposure from the phone was causing brain tumours, it would be expected that analogue and digital MPs would result in more tumours than cordless phones, but this is not the pattern that is seen in the data. Particularly as there is the inherent difficulty in explaining how tumours that are thought to have different aetiologies could be caused by the same factor, it is thus important to look to see whether factors other than the dose relations can support the inconsistently increased analogue risks. The patterning of the results does not provide any more support for a relation. Cumulative exposure was consistently unrelated to diagnosis 13, 20, 22, 24, 27 , and latency was related to ORs in Auvinen et al 27 (with a restricted latency range) but not the other studies 13, 19, 20, 22, 24, 34 . Similarly, laterality was related to ORs only in Hardell et al 13 , where larger ORs were reported for ipsilateral than contralateral tumours, but not in other studies 20, 22, 24 , and this laterality effect was found for cordless as well as analogue and digital. Coupled with the difficulty in explaining why these tumours with different aetiologies should be similarly affected by MP energy, why such a restricted latency should be related to outcome 27 , and why these relationships should also be present with cordless phones, the inconsistency of the grouped tumour-type literature does not provide evidence that MP use is related to primary brain tumours in general.
Overall summary of research to date
In the four studies assessing trends over time within populations (Switzerland, New Zealand, Sweden, Norway, Denmark, Finland) [14] [15] [16] [17] , no evidence was found of an increase in intracranial tumour incidence or mortality rate that corresponded to the increased use of MPs in these countries (since late 1980s-early 1990s). These null findings are supported by the only large-scale retrospective cohort study and the four hospital-based case-control studies, where an association between MP use and intracranial tumours was not found. This suggests that there is not a strong association between MP use and intracranial tumours, but leaves open the possibility that MPs may result in a small increase of intracranial tumours.
Population-based case-control studies have also failed to identify a clear association between MP-use and intracranial tumours. In terms of overall associations (independent of such factors as latency and laterality), it is clear that there is no convincing evidence indicating a relation between MP use and acoustic neuroma, meningioma, glioma, or combined brain tumours. However, for more specific sub-analyses the situation is more ambiguous. The main issue that is still undecided is whether there is a small relationship between acoustic neuroma or glioma, and the reported use of a MP for more than 10 years ipsilateral to the tumour 35, 36 . The reported laterality of the association is consistent with a doserelationship, the latency is consistent with the time that it can take tumours to develop, and it is certainly possible that the lack of consistent effects reported in the literature could be due to the extremely small risk. However, as the number of cases in such positive analyses are low, as the ORs are very close to 1, as the relations are similar for tumours with very different aetiologies and courses, and as interpretation of such laterality analyses is problematic due to the possibility of reporting bias, further research is required before this issue can be resolved.
Interphone and unanswered questions
The pooled results from Interphone will soon be released, and given that it will provide the largest and most meticulous epidemiological assessment of MPs and tumours to date, it is useful to consider how the results from Interphone would impact on the above conclusions.
A strength of Interphone is that it is a multi-centre study with very similar methods that will be able to report risks from a very large number of cases. For example, the number of acoustic neuroma, meningioma and glioma cases will be 1,121, 2,425 and 2,765 respectively 2 . This will provide the ability to detect very small increases in risk, and thus will be able to overcome the limitations described above with individual studies and meta-analyses in this area. If the reason for failing to detect consistent relations between overall MP use and various tumours in the literature was low statistical power, this would be largely resolved with the pooled Interphone analyses. Similarly, if the large ORs reported in some studies 13, 28, 34 represent real relationships between tumours and MP use, then Interphone should confirm this.
However, the situation is less clear with regard to subgroup analyses. This is particularly important for the suggestion of relationships between acoustic neuroma / glioma, and ipsilateral MP-use of more than 10 years. Although the number of cases will be far greater than have been reported previously for this sub-group, whether there are enough to be confident with the results remains to be seen. An estimate of what can be expected can be obtained by considering the papers by Schoemaker et al 35 and Lakhola et al 36 , which contain about half (678 acoustic neuroma and 1521 glioma cases respectively) of the final pooled sample reported in Cardis et al 2 . Schoemaker et al 35 and Lahkola et al 36 had only 23 and 77 cases (respectively) from this subgroup, and if we assume a similar proportion of cases in that paper to the remainder of Interphone, this would result in <150 cases. This would not provide the same degree of power as the main analyses, and given this it is unlikely that the 'ipsilateral / >10 years' risk will be large enough to be more than suggestive.
As previously noted, even if Interphone unambiguously demonstrated either a strong association or no association, this would not provide sufficient evidence for or against causation. This is because there are limitations with the methodology that leave open alternate explanations. For example, the lack of strong dosimetry 50 and the related possibility of bias in this form of case-control study increases ambiguity, as does the difficulty of ascertaining the temporal sequence of the exposure and outcome. Perhaps most important to causation at present is the lack of biological plausibility that could help explain how such a causal association could occur. Thus even if there are positive results from Interphone, they could not be seen as demonstrating causation, but only an extremely important association in need of further exploration.
One issue not well addressed in Interphone is long term use (>10 years). For latency analyses it is necessary for there to be a sufficient time from the first exposure for tumours to develop, but as widespread use of MPs is a relatively recent phenomenon there are not large numbers of subjects to recruit to the long term analyses. In addition, a challenge with all the studies described including Interphone, is that due to the continuous evolution of technologies, it is difficult to test for associations between tumours and the same sort of exposures for greater than about ten years. For example, as analogue MPs are not typically used today, exposure to analogue phones does not keep accumulating. This means that there also may not be an opportunity to employ epidemiological techniques to address the issue of long-term exposure to particular technologies.
Conclusions
When the epidemiology literature pertaining to MP use and brain and head tumours is considered as a whole, there is no convincing evidence to date of an association. The only possible exception to this is for research that has looked at acoustic neuroma and glioma cases that have used MPs for > 10 years, and on the same side of the head as the tumour. This data indicates a possible association, but it is too premature to conclude that there is an association. Furthermore, while the forthcoming combined Interphone analysis will be able to confirm/refute the majority of the above conclusions, it is still not clear that it will have sufficient power to clarify whether there is an association between acoustic neuroma or glioma and ipsilateral MP use for greater than 10 years. In addition, as discussed in this paper, reported associations with laterality are prone to such significant uncertainty, due to the effect of reporting bias and other systematic biases, that they are unlikely to be of utility unless the laterality comparison results are very stark indeed.
